Journal of hepatocellular carcinoma · 2026
DEB-TACE Combined with Immunotherapy and Targeted Therapy for Advanced Hepatocellular Carcinoma with Scapular Metastasis: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Wenxia, Kang Dongxu, Xu Qiang, Piao Longzhen
Аннотация
BACKGROUND: Advanced hepatocellular carcinoma (HCC) with massive intrahepatic tumors and bone metastases is associated with poor prognosis, and standard treatment options are limited. Bone metastases, particularly to rare sites such as the scapula, pose additional therapeutic challenges.
CASE PRESENTATION: We report a patient with a giant intrahepatic HCC and scapular metastasis. The patient received three sessions of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with systemic therapy using lenvatinib and camrelizumab. Marked radiological regression and improvement in tumor markers were observed. The patient remained progression-free at the last documented follow-up of 16 months.
CONCLUSION: The combination of DEB-TACE, lenvatinib, and camrelizumab for treating advanced hepatocellular carcinoma with scapular metastasis was shown to be feasible in this case and was associated with sustained disease control of both intrahepatic and extrahepatic lesions.
CASE PRESENTATION: We report a patient with a giant intrahepatic HCC and scapular metastasis. The patient received three sessions of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with systemic therapy using lenvatinib and camrelizumab. Marked radiological regression and improvement in tumor markers were observed. The patient remained progression-free at the last documented follow-up of 16 months.
CONCLUSION: The combination of DEB-TACE, lenvatinib, and camrelizumab for treating advanced hepatocellular carcinoma with scapular metastasis was shown to be feasible in this case and was associated with sustained disease control of both intrahepatic and extrahepatic lesions.